ENXTPA:ALPHS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Pharmasimple SA operates a Website for medicines, cosmetics, and food supplements in Belgium and France. More Details


Snowflake Analysis

Reasonable growth potential with worrying balance sheet.

Share Price & News

How has Pharmasimple's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ALPHS has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-1.4%

ALPHS

3.5%

FR Online Retail

-0.6%

FR Market


1 Year Return

67.2%

ALPHS

11.5%

FR Online Retail

-7.7%

FR Market

Return vs Industry: ALPHS exceeded the French Online Retail industry which returned 11.5% over the past year.

Return vs Market: ALPHS exceeded the French Market which returned -7.7% over the past year.


Shareholder returns

ALPHSIndustryMarket
7 Day-1.4%3.5%-0.6%
30 Day6.3%10.5%2.0%
90 Day-4.2%19.8%1.5%
1 Year67.2%67.2%26.9%11.5%-5.7%-7.7%
3 Year-64.2%-64.2%-58.6%-74.7%8.5%-0.9%
5 Yearn/a150.2%140.6%40.7%21.7%

Price Volatility Vs. Market

How volatile is Pharmasimple's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Pharmasimple undervalued compared to its fair value and its price relative to the market?


Share Price vs. Fair Value

Below Fair Value: ALPHS (€10.2) is trading above our estimate of fair value (€5.97)

Significantly Below Fair Value: ALPHS is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: Insufficient data to calculate ALPHS's PE Ratio to determine if it is good value compared to the FR Online Retail industry average.

PE vs Market: Insufficient data to calculate ALPHS's PE Ratio to determine if it is good value compared to the French market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALPHS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: Insufficient data to calculate ALPHS's PB Ratio to determine if it is good value.


Next Steps

Future Growth

How is Pharmasimple forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

93.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALPHS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.6%).

Earnings vs Market: ALPHS is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ALPHS's is expected to become profitable in the next 3 years.

Revenue vs Market: ALPHS's revenue (14.6% per year) is forecast to grow faster than the French market (6.7% per year).

High Growth Revenue: ALPHS's revenue (14.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ALPHS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Pharmasimple performed over the past 5 years?

-37.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ALPHS is currently unprofitable.

Growing Profit Margin: ALPHS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ALPHS is unprofitable, and losses have increased over the past 5 years at a rate of 37.2% per year.

Accelerating Growth: Unable to compare ALPHS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALPHS is unprofitable, making it difficult to compare its past year earnings growth to the Online Retail industry (-9.5%).


Return on Equity

High ROE: ALPHS has a negative Return on Equity (-90.79%), as it is currently unprofitable.


Next Steps

Financial Health

How is Pharmasimple's financial position?


Financial Position Analysis

Short Term Liabilities: ALPHS's short term assets (€8.6M) do not cover its short term liabilities (€10.2M).

Long Term Liabilities: ALPHS's short term assets (€8.6M) exceed its long term liabilities (€5.9M).


Debt to Equity History and Analysis

Debt Level: ALPHS's debt to equity ratio (282.3%) is considered high.

Reducing Debt: ALPHS's debt to equity ratio has increased from 108.5% to 282.3% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if ALPHS has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ALPHS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Pharmasimple current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALPHS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALPHS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALPHS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALPHS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ALPHS's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.2yrs

Average board tenure


CEO

Michael Willems

6.92yrs

Tenure

Mr. Michaël Willems has been the Chief Executive Officer and Chairman of Pharmasimple SA since October 31, 2013.


Board Members

NamePositionTenureCompensationOwnership
Michael Willems
Chairman & CEO6.92yrsno datano data
Stephane Moity
Director5.17yrsno datano data
Alexandre Plissart
Director3yrsno datano data

5.2yrs

Average Tenure

Experienced Board: ALPHS's board of directors are considered experienced (5.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 85.3%.


Top Shareholders

Company Information

Pharmasimple SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Pharmasimple SA
  • Ticker: ALPHS
  • Exchange: ENXTPA
  • Founded: 2010
  • Industry: Internet and Direct Marketing Retail
  • Sector: Retail
  • Market Cap: €29.474m
  • Shares outstanding: 2.89m
  • Website: https://www.pharmasimple.com

Number of Employees


Location

  • Pharmasimple SA
  • Millennium Boulevard 11
  • Houdeng-Goegnies
  • Hainaut
  • 7110
  • Belgium

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALPHSENXTPA (Euronext Paris)YesBearer SharesFREURNov 2016

Biography

Pharmasimple SA operates a Website for medicines, cosmetics, and food supplements in Belgium and France. It offers beauty and cosmetics products, such as face wash, face care, make-up, hair removal, body c ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/20 02:58
End of Day Share Price2020/09/18 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.